Uveal ‘Clusters’ in Auburn, AL and Huntersville, NC
When we talk about melanoma, it’s easy to forget that cutaneous – the most common variety that forms on the skin – isn’t the only game in town. Uveal represents about 5% of all melanomas diagnosed each year. So, when dozens of people from two towns in North Carolina and Alabama were diagnosed with the rare cancer alarm bells sounded.
Self-Care is Non-Negotiable: “How Early Detection Saved My Life”
Jackie Labrecque’s life changed with a single phone call when her dermatologist called to tell her that the mole that she tried to ignore for months was melanoma.
We’ve Teamed Up with the American Cancer Society
American Cancer Society and Melanoma Research Alliance have united to fund lifesaving research aimed at reducing side effects and improving outcomes for patients treated with immunotherapy.
Why it Matters: U.S. Preventive Services Task Force Endorses Skin Cancer Prevention Counseling for Children and Young Adults
This government-backed panel just put skin cancer prevention counseling on the map.
American Cancer Society and Melanoma Research Alliance Fund Five Innovative Approaches to Reduce Immunotherapy Side Effects
As the world marks Melanoma Awareness Month, the American Cancer Society (ACS) and the Melanoma Research Alliance (MRA) selected the first group of scientists to receive newly established research grants to investigate how to reduce rare, but serious, side effects resulting from cancer treatments with checkpoint inhibitors, a type of immunotherapy.
Melanoma Awareness Month: Opportunities to Make a Difference
Melanoma Awareness Month, held in May each year, is a wonderful opportunity to raise awareness of the dangers of melanoma, the importance of early detection, and the many ways to practice sun safety. From talking about sun safety to your friends and family, taking the Skin Check Pledge, posting about melanoma on social media, or highlighting prevention strategies in your organization newsletter—there are many ways we can all take part and make a difference!
Tackling Brain Metastases
Brain metastases (mets) are a frequent and often deadly problem in patients with advanced melanoma. Nearly 40% of patients with metastatic melanoma have brain mets at diagnosis, with an average survival of only 4 months, suggesting a crucial need for treatments that can rid the brain of these tumors1,2. But new cancer treatments are rarely tested in patients with active brain mets. This is largely due to concerns about whether these patients will have side effects unique to brain mets, and poorer outcomes that may negatively weigh against otherwise positive clinical benefits. Another potential concern is whether the drugs will even penetrate the brain, which has a fortress-like ability to keep substances from entering it.